Beyond the Glycaemic Control of Dapagliflozin: Impact on Arterial Stiffness and Macroangiopathy

Dapagliflozin is a selective sodium–glucose cotransporter 2 inhibitor (SGLT2i) indicated for the treatment of type 2 diabetes mellitus (T2DM), heart failure with reduced ejection fraction and chronic kidney disease. In all indications, treatment can be initiated in adults with estimated glomerular f...

Descripción completa

Detalles Bibliográficos
Autores principales: González-Clemente, José M., García-Castillo, María, Gorgojo-Martínez, Juan J., Jiménez, Alberto, Llorente, Ignacio, Matute, Eduardo, Tejera, Cristina, Izarra, Aitziber, Lecube, Albert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240142/
https://www.ncbi.nlm.nih.gov/pubmed/35687260
http://dx.doi.org/10.1007/s13300-022-01280-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240142/
https://www.ncbi.nlm.nih.gov/pubmed/35687260
http://dx.doi.org/10.1007/s13300-022-01280-6

Ejemplares similares